BIIB

Biogen Inc. is a global biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines primarily for serious neurological, neuro‑degenerative and rare diseases. Its core portfolio includes multiple‑sclerosis therapies such as Tecfidera, Vumerity, Avonex, Plegridy and Tysabri, as well as treatments for spinal muscular atrophy (Spinraza), Friedreich’s ataxia (Skyclarys) and amyotrophic lateral sclerosis (Qalsody). The firm operates within the biotechnology sector and is recognized as one of the earliest and largest companies dedicated to neuroscience, leveraging deep scientific expertise, sterile biologics manufacturing and strategic partnerships. Biogen’s market position is anchored by a longstanding multiple‑sclerosis franchise and a growing pipeline of rare‑disease and neuro‑degenerative candidates.